Sana Biotechnology (SANA) Cash from Operations (2020 - 2026)
Sana Biotechnology (SANA) posted Cash from Operations of 37379000.0 for Q1 2026, down 14.52% sequentially from 32641000.0 in Q4 2025, and up 23.18% YoY from 30345374.21 in Q1 2025.
Powered by 
Analysis
Sana Biotechnology (SANA) Cash from Operations (2020 - 2026) Analysis & Trends
Sana Biotechnology has reported Cash from Operations for 7 years, with the latest figure at 37379000.0 in Q1 2026.
- Quarterly Cash from Operations rose 23.18% year-over-year to 37379000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 132550000.0 (up 35.71% YoY) and the FY2025 annual result came in at 143828000.0, up 35.55% from the prior year.
- Cash from Operations slipped to 37379000.0 in Q1 2026 per SANA's latest filing, from 32641000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 29429000.0 in Q3 2025 and troughed at 79272000.0 in Q1 2023.
- A 5-year average of 55764235.29 and a median of 58541000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 76.25% in 2022, then surged 43.46% in 2025.
- Over 5 years, Cash from Operations stood at 76067000.0 in 2022, then soared by 31.69% to 51959000.0 in 2023, then gained by 9.23% to 47161000.0 in 2024, then jumped by 30.79% to 32641000.0 in 2025, then dropped by 14.52% to 37379000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 37379000.0, 32641000.0, and 29429000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Sana Biotechnology | 1.14 Bn | 1.14 Bn | - | -32.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -32.79 Mn |
| Mar 31, 2026 | -37.38 Mn |
| Dec 31, 2025 | -32.64 Mn |
| Sep 30, 2025 | -29.43 Mn |
| Jun 30, 2025 | -33.10 Mn |
| Mar 31, 2025 | -48.66 Mn |
| Dec 31, 2024 | -47.16 Mn |
| Sep 30, 2024 | -51.82 Mn |
| Jun 30, 2024 | -58.54 Mn |
| Mar 31, 2024 | -65.63 Mn |
| Dec 31, 2023 | -51.96 Mn |
| Sep 30, 2023 | -63.55 Mn |
| Jun 30, 2023 | -58.80 Mn |
| Mar 31, 2023 | -79.27 Mn |
| Dec 31, 2022 | -76.07 Mn |
| Sep 30, 2022 | -64.80 Mn |
| Jun 30, 2022 | -71.48 Mn |
| Mar 31, 2022 | -77.71 Mn |
| Dec 31, 2021 | -110.10 Mn |
| Sep 30, 2021 | -50.49 Mn |